Arovella Therapeutics Limited · ASX:ALA
Arovella Therapeutics — Shareholder Meeting (November 2020)
14 slides from Arovella Therapeutics's shareholder meeting presentation, Nov 26, 2020
Slide 1: SUDA Annual General Meeting
SUDA Annual General Meeting 26 November 2020 © Copyright SUDA Pharmaceuticals Ltd 2020
Slide 2: The Year In Review
The Year In Review Anagrelide Patent Granted – Richard Franklin Appointed Project Japan Anagrelide Patent Granted – Director of the Anagrelide Program MAY 2020 Australia AUG 2019 SEP 2020 Transaction For Oncology Management Changes – Ordesa Deal Asset Terminated Steve Carter Resignation DEC 2019 JUN
Slide 3: Company Highlights
Company Highlights ▪ Board and Management Focus on Portfolio Technology Platform – OroMist™ Expansion: Actively seeking new deal flow for technologies with a focus on oncology and the central nervous system ▪ Unique Platform Technology – OroMist™: Reformulate existing billion-dollar drugs for oral d
Slide 4: Expanding our Portfolio
Expanding our Portfolio ▪ Over 18 months SUDA has refreshed the board and senior management group ▪ The team has expertise in sourcing, evaluating and acquiring novel technologies ▪ SUDA’s key areas of focus are oncology and the central nervous system ▪ SUDA will continue to source deal flow and loo
Slide 5: Board & Senior Management
Board & Senior Management Chairman CEO & Managing Director Executive Director Director Paul Hopper Dr. Michael Baker David Phillips David Simmonds Over 25 years experience in the Over 15 years experience in scientific Senior Business Development Executive David was a senior audit partner with medica
Slide 6: Business Strategy - Develop and License
Business Strategy - Develop and License License Internal Sales Drug Regulatory Development Feasibility Preclinical Clinical trials Approved (royalties) Submissions ZolpiMist (insomnia) Sumatriptan (migraine) Medical Grade Target Assets Cannabis Undisclosed Anagrelide (solid tumours) Value 6 © Copyri
Slide 7: ZolpiMist – Achievements in 2020
ZolpiMist – Achievements in 2020 Background ▪ ZolpiMist is SUDA’s spray version of the insomnia drug Ambien ▪ Ambien was Sanofi’s blockbuster insomnia drug ▪ SUDA has rest-of-world rights ex-North America, and license and supply agreements with Teva and Mitsubishi Tanabe Pharma Singapore Achievement
Slide 8: Anagrelide – Achievements in 2020
Anagrelide – Achievements in 2020 Background ▪ Approved generic drug to treat a rare blood disorder where a patient’s platelet count is too high ▪ Cancer patients with high platelet counts have a poor prognosis, literature suggests that lowering the platelet count will play an important role in incr
Slide 9: SUDA – Progress in 2020
SUDA – Progress in 2020 ▪ CEO integration ▪ Successful integration, maintenance of key projects, increased focus ▪ Dr Baker joined the Board of Directors ▪ Close pharma deals ▪ Ordesa ▪ Sanofi ▪ Mitsubishi Tanabe Pharma Korea ▪ Opportunistically review other assets ▪ New assets have been identified
Slide 10: SUDA's Market Communications – Continuing in 2021
SUDA’s Market Communications – Continuing in 2021 ▪ Primary avenue for dissemination of news is the ASX ▪ Primary spokesperson is the CEO ▪ No selective disclosure ▪ No discussion by way of private emails ▪ No discussion by way of private telephone calls ▪ ASX releases: factual, no hype, conservativ
Slide 11: SUDA's Market Communications – Continuing in 2021
SUDA’s Market Communications – Continuing in 2021 Communication Type Number Social Media Engagement CEO Interview 9 450 Jan Nov Conference Presentation 4 400 News Article 4 350 Analyst Report 4 300 FOLLOWERS 250 Newsletter 2 200 CEO Letter 2 150 Podcast 2 100 50 Investor Roadshow 2 0 LinkedIn Twitte
Slide 12: Our Focus For The Year Ahead
Our Focus For The Year Ahead ▪ ZolpiMist commercialization ▪ Anagrelide formulation stabilisation and preclinical studies ▪ Acquire and integrate new assets – oncology and CNS ▪ Manage costs ▪ Maintain shareholder communications and focus on investor confidence License Internal Sales Development Reg
Slide 13: Thank You
Thank You The CFO Solution Level 3 62 Lygon Street Carlton VIC 3053 (T) +61 8 6142 5555 (F) +61 8 9443 8858 © Copyright SUDA Pharmaceuticals Ltd 2020
Slide 14: Disclaimer
Disclaimer The purpose of the presentation is to provide an update of the business of SUDA PHARMACEUTICALS LTD (ASX:SUD) [‘SUDA’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slid
Arovella Therapeutics — Shareholder Meeting (November 2020) on 6ix